BeOne Medicines AG
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John V. Oyler
- Full Time Employees
- 12,000
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Aeschengraben 27 Basel PA Switzerland 4051
- IPO Date
- Feb 3, 2016
- CIK
- 0001651308
- Website
- beonemedicines.com
- Similar Companies
- Business
- BeOne Medicines Ltd. (ONC) is a global oncology company that discovers, develops and commercializes innovative cancer treatments spanning hematology and solid tumors; its marketed products include BRUKINSA (zanubrutinib), a second-generation BTK inhibitor approved for chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström's macroglobulinemia; TEVIMBRA (tislelizumab), a PD-1 inhibitor approved for Hodgkin lymphoma, esophageal squamous cell carcinoma, gastric/gastroesophageal junction adenocarcinoma and small cell lung cancer; and others such as pamiparib and denosumab; the company advances a diverse pipeline of novel therapeutics including sonrotoclax (BCL2 inhibitor), BGB-16673 (BTK degrader), BGB-43395 (CDK4 inhibitor), BG-68501 (CDK2 inhibitor), xaluritamig (STEAP1 x CD3 bispecific), TARLATAMAB-DLLE (CD3 x DLL3 bispecific), antibody-drug conjugates like BG-C9074, bispecific T-cell engagers and PROTACs through internal R&D and collaborations. BeOne Medicines operates in over 45 countries across six continents with major presence in the United States, China, Europe, Australia and Asia; it was founded in 2010 by John V. Oyler and Xiaodong Wang, and is headquartered in Basel, Switzerland following redomiciliation in May 2025 from Cambridge, Massachusetts. Recent developments include a November 2024 rebranding from BeiGene Ltd. with stock ticker change to ONC in January 2025; an August 2025 royalty purchase agreement with Royalty Pharma for up to $950 million on IMDELLTRA (tarlatamab-dlle) sales excluding China, providing $885 million upfront; positive Phase 3 results in August 2025 for sonrotoclax in relapsed/refractory chronic lymphocytic leukemia; European Commission approval in August 2025 for TEVIMBRA as neoadjuvant/adjuvant treatment for non-small cell lung cancer; 41% total revenue growth to $1.4 billion in Q3 2025 driven by 51% increase in global BRUKINSA sales; and pipeline advancements showcased at ASH 2025 including long-term BRUKINSA data and new combinations in B-cell malignancies.
Company News
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne Medicines (NASDAQ:ONC) Insider Sells $10,890,166.73 in Stock
All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy
New Strong Buy Stocks for October 15th
Comparing Aurora Cannabis (NASDAQ:ACB) & BeOne Medicines (NASDAQ:ONC)
Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving Average – Here’s Why
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $402.71
Head-To-Head Analysis: BeOne Medicines (NASDAQ:ONC) versus NRx Pharmaceuticals (NASDAQ:NRXP)
BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BeOne Medicines (NASDAQ:ONC) Insider Sells $13,365,991.70 in Stock
Oncolytics Biotech (TSE:ONC) Shares Pass Above Two Hundred Day Moving Average – Here’s Why
Nykredit A S Invests $1.20 Million in BeOne Medicines Ltd. – Sponsored ADR $ONC
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA